FMT for Alcohol Use Disorder in Cirrhotics.

Last updated: July 27, 2024
Sponsor: Institute of Liver and Biliary Sciences, India
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alcohol Use Disorder

Addictions

Substance Abuse

Treatment

SMT

FMT

Placebo

Clinical Study ID

NCT06496191
ILBS-FMT-03
  • Ages 18-70
  • All Genders

Study Summary

  • Title "FMT for Alcohol Use Disorder in cirrhotics: A Randomized Controlled Trial"

  • The aim of the study is to study the efficacy of Fecal microbiota transplantation in patients with Alcohol liver disease over a 6 month duration without liver related side effects. The project will be conducted at ILBS over the period of 1 year.

  • The concept is to test the efficacy of FMT in alcohol related cirrhotics by its effect on achieving and maintaining abstinence and in reducing lapses and relapses. Thereby reducing the progression of alcoholic liver disease as continued ethanol consumption is an important predictor in increasing overall morbidity and mortality.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. All consecutive patients with alcohol related cirrhosis with serum bilirubin <5mg/dlwith an active alcohol consumption atleast within last 4 weeks aged between 18 -70yrs.

  2. Fulfilling DSM - 5 criteria for alcohol use disorder (Association, 2013).

Exclusion

Exclusion Criteria:

  1. Pregnancy

  2. Acute illness or fever on the day of planned FMT

  3. Ongoing/Past 2 weeks antibiotic use

  4. Unclear diagnosis of CLD

  5. Non-elective hospitalization within last month

  6. Serum bilirubin >5mg/dl

  7. Grade 2 or more Ascites

  8. Any Episode of HE Grade 2 or more or requiring hospital admission within 3 months

  9. Episode of AVB within last 3 months

  10. Treatment with corticosteroids/Immunosupression within the past 60 days

  11. Unwilling to participate

  12. Dependence on any other substance (except Nicotine)

  13. Psychiatric disorder requiring pharmacotherapy/Suicidal tendency

  14. Known untreated, in-situ luminal GI cancers & chronic intrinsic GI diseases.

Study Design

Total Participants: 54
Treatment Group(s): 3
Primary Treatment: SMT
Phase:
Study Start date:
July 27, 2024
Estimated Completion Date:
June 30, 2025

Study Description

Hypothesis :- - FMT is useful in reducing craving and return to heavy drinking in patients with alcohol related cirrhosis with active drinking, through modulation of gut microbiota and correction of dysbiosis

Aim and Objective -

  • To assess the efficacy of FMT in decreasing lapse, relapses and maintaining alcohol abstinence in AUD in patients with cirrhosis

Study population:

  • Patients with cirrhosis with recent alcohol use attending outpatient clinic at ILBS, New Delhi

Study design:

  • Open label, parallel group, randomized, controlled study.

Study period:

  • 1 year

Sample size with justification:

  • Assuming that abstinence in Placebo group is 50% and we assume that there will be 40% absolute increase in FMT group (90%; Bajaj JS, Hepatology 2021) with alpha 5 and power of 80%, investigator need to enroll 48 cases, further assuming 10 % dropout rate it was decided to enroll 54 cases that is 27 in each group.

Connect with a study center

  • Institute of Liver & Biliary Sciences (ILBS)

    New Delhi, Delhi 110070
    India

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.